Altimmune (ALT) EBITDA (2010 - 2026)

Altimmune (ALT) has 17 years of EBITDA data on file, last reported at -$24.2 million in Q1 2026.

• On a quarterly basis, EBITDA fell 11.13% year-over-year to -$24.2 million in Q1 2026; TTM through Mar 2026 was -$96.9 million, a 1.3% increase from a year earlier, with the FY2025 full-year figure at -$94.5 million, up 8.42% from the prior year.
• EBITDA for Q1 2026 stood at -$24.2 million, up from -$28.9 million in the prior quarter.
• Over the last five years, EBITDA for ALT reached as high as -$18.0 million in Q2 2023 and fell as low as -$33.6 million in Q4 2023.
• Historically, EBITDA has averaged -$23.9 million across 5 years, with a median of -$23.1 million in 2022.
• On a YoY basis, EBITDA climbed as much as 26.04% in 2024 and fell as far as 48.53% in 2024.
• Year by year, EBITDA stood at -$23.1 million in 2022, then tumbled by 45.59% to -$33.6 million in 2023, then increased by 26.04% to -$24.9 million in 2024, then fell by 16.19% to -$28.9 million in 2025, then grew by 16.09% to -$24.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$24.2 million in Q1 2026, -$28.9 million in Q4 2025, and -$20.9 million in Q3 2025.